Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplastic Syndrome

Myelodysplastic Syndromes Clinical Trial

— SMD-transfu  

Official title:

Impact of 2 Transfusion Strategies on the Quality of Life of Multi-transfused Patients With Low Risk Myelodysplastic Syndrome: Multicenter Randomized Trial Comparing a Liberal vs. Restrictive Transfusion Regimen

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03643042
• Other study ID #: RC-P0071
• Status: Terminated
• Phase: N/A
• Start date: March 24, 2021
• Est. completion date: March 22, 2023

Study information

• Verified date: June 2023
• Source: Lille Catholic University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Myelodysplastic syndromes (MDS) are heterogeneous malignant bone marrow disorders characterized by ineffective haematopoiesis, peripheral blood cytopenias and variable risk of leukaemia transformation. Anemia is the most common manifestation of bone marrow failure in MDS. After failure with first-line treatment by Erythropoietin, patients survive in average 5 years under long term blood transfusion. Modalities of blood transfusion are not clearly defined. Then, the objective of this randomized comparative multicentric study is to compare two modalities of threshold for transfusion: - Restrictive group: Hb < 80g/L and Hb maintain between 80 and 100g/L - Liberal group: Hb < 100g/L and Hb maintain between 100 and 120g/L

Description:

Myelodysplastic syndromes (MDS) are heterogeneous malignant bone marrow disorders characterized by ineffective haematopoiesis, peripheral blood cytopenias and variable risk of leukaemia transformation. The median age at diagnosis is 75 years. The incidence is about 30 per 100,000, over 70 years. Etiology is unknown in more than 85% of cases, chemo-induced causes and family cases are well individualized. Diagnosis, prognosis, and classification (WHO) are based on joint cytologic analysis of peripheral blood, bone marrow, and spinal cytogenetic analysis. The main therapeutic objectives in low-risk MDS are to correct cytopenias, improve quality of life and prevent aggravation of co-morbidities. Anemia is the most common manifestation of bone marrow failure in MDS. It is encountered in 80% of cases at diagnosis and almost always occurs in the progression of the disease. Its presence and importance have a pejorative prognostic value, but it is not clear whether this anemia is indicative of a more serious clonal disease or whether it is the repercussions of anemia that lead to a more severe prognosis. After failure with first-line treatment by Erythropoietin (EPO), patients survive in average 5 years under long term blood transfusion. Modalities of blood transfusion are not clearly defined. Studies in the general geriatric population and in cases of acute anemia are in favor of a restrictive transfusion regimen (threshold around 70 g/L), while experience during MDS with EPO suggest that maintaining a higher hemoglobin count could have a favorable impact on quality of life, physical performance, or even survival of patients with MDS. Then, the objective of this randomized comparative multicentric study is to compare two modalities of threshold for transfusion: - Restrictive group: Hb < 80g/L and Hb maintain between 80 and 100g/L - Liberal group: Hb < 100g/L and Hb maintain between 100 and 120g/L

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: March 22, 2023
• Est. primary completion date: September 21, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with low risk or intermediate risk MDS: Revised International Prognostic Scoring System (IPSS-R) less than or equal to 4.5
• Relapse or failure after Erythropoiesis-Stimulating Agent (ESA) therapy or others treatments (Lenalidomide, Thalidomide, 5-Azacytidine, antithymocyte globulin (ATG), Luspatercept, Decitabine, allograft)
• Transfusion dependent: in average at least 3 transfusion episodes in the last 6 months and total of packed red blood cells (PRBC): more than 8 in the last 12 months and less than 150 in total.
• = 18 years of age
• The Eastern Cooperative Oncology Group (ECOG) score < 4
• Life expectancy > 12 Months
• Patients willing to participate in the study and who have signed the informed consent form

Exclusion Criteria:

• Patients with disease modifying agents for their MDS such as: ESA therapy, Lenalidomide, Thalidomide revlimid, Vidaza, Allograft, antithymocyte globulin (ATG), Luspatercept, Decitabine, experimental agents, other clinical trial, taken within 3 months prior to inclusion (chelators are accepted)
• According to physician: unable to tolerate restrictive or liberal red cell transfusion thresholds (e.g. clinically significant cardio-respiratory failure)
• Cognitive alteration (inability to complete QUALMS)
• Inability to perform the physical performance test Timed up and go test
• Splenomegaly > 3 cm below the costal margin
• Severe renal failure with creatinine clearance < 30ml / min
• Patients presenting with active bleeding or evidence of significant haemolysis
• Patient under guardianship or curatorship

Related Conditions & MeSH terms

• Myelodysplastic Syndromes
• Preleukemia
• Syndrome
• Transfusion-dependent Anemia

Intervention

Other:
• Transfusion
Transfusion with Hb maintain between 80 and 100g/L or Hb maintain between 100 and 120g/L

Locations

Country	Name	City	State
France	Abbeville CH	Abbeville
France	Amiens CHU	Amiens
France	Arras CH	Arras
France	Henri Duffaut CH	Avignon
France	Besançon CHU	Besançon
France	Bordeaux CHU	Bordeaux
France	Cote de Nacre CHU	Caen
France	Clermont-Ferrand CHU	Clermont-Ferrand
France	Dunkerque CH	Dunkerque
France	Grenoble CHU	Grenoble
France	Le Mans CH	Le Mans
France	Lens CH	Lens
France	St-Vincent Hospital	Lille
France	Limoges CHRU	Limoges
France	Meaux CH	Meaux
France	Archet 1 Hospital	Nice
France	Saint-Louis Hospital, APHP	Paris
France	Pontchaillou Hospital	Rennes
France	Roubaix CH	Roubaix

Sponsors (1)

Lead Sponsor	Collaborator
Lille Catholic University

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quality of Life by Myelodysplasia Scale (QUALMS) score	Quality of Life assessed by a specific validated and adapted disease scale :Quality of Life by Myelodysplasia Scale (QUALMS) score at six months post-randomization. The QUALMS consists of 38 items, and takes less than 10 minutes to complete. Scored on a scale of 0 to 100 higher score is correlated with better MDS-specific quality of life.	six months post-randomization
Secondary	Quality of Life by Myelodysplasia Scale (QUALMS) score over the twelve months of follow-up	Evolution of the QUALMS score over the twelve months of follow-up. Scored on a scale of 0 to 100 higher score is correlated with better MDS-specific quality of life.	3, 6, 12 Months
Secondary	Timed up and go test over the twelve months of follow-up	Evolution of physical performance (the time required for the Timed up and go test) at six months post-randomization and over the twelve months of follow-up	3, 6, 12 Months
Secondary	Transfusion incidents rate over the twelve months of follow-up	Transfusion incidents rate during the twelve months of follow-up among allo-immunization, hospitalization for pulmonary overload, iron overload (ferritin, transferrin saturation), TRALI (Transfusion-Related Acute Lung Injury)	3, 6, 12 Months
Secondary	Transfusion costs over the twelve months of follow-up	Transfusion costs (number of Packed red blood cells (PRBC) used) during the twelve months of follow-up	3, 6, 12 Months
Secondary	Time of occurrence of diagnosis of heart and liver damage due to transfusional iron overload over twelve months of follow-up	Time of occurrence of diagnosis of heart and liver damage due to transfusional iron overload over twelve months of follow-up. The diagnosis will be established according to the standard procedure based on annual MRI, in particular by measuring the LIC (liver iron concentration), the MIC (myocardial iron concentration) and the cardiac T2* value.	3, 6, 12 Months